TMX3

TMX3 is an endoplasmic reticulum-resident type I transmembrane thiol-disulfide oxidoreductase of the PDI family that participates in oxidative protein folding and redox-dependent cellular processes (PMID:15623505). Its ER-luminal region adopts a three thioredoxin-like domain architecture in which a single N-terminal redox-active 'a' domain carries the CGHC active site while the catalytically inactive 'b' domain stabilizes the redox-active domain against denaturation and proteolysis in both oxidation states (PMID:17881353); the luminal domain exhibits oxidase activity in vitro with a redox potential of −0.157 V, comparable to PDI and ERp57, and is anchored to the ER membrane via a C-terminal KKXX-type retrieval signal (PMID:15623505). TMX3 is not engaged by the Ero1α oxidase pathway that re-oxidizes other PDI-family members, distinguishing its route of catalytic-cysteine reoxidation (PMID:20802462). Functionally, its redox-active domain is required for vertebrate eye morphogenesis, since wild-type but not a patient-derived active-site-region missense mutant rescues the microphthalmia-like phenotype of TMX3 knockdown in zebrafish (PMID:20485507). TMX3 also promotes ER-mitochondria communication and constrains mitochondrial and NOX4-derived ROS to sustain NFAT1-driven melanoma proliferation and tumor growth (PMID:31304984), and it acts as an essential cofactor enabling functional heterologous assembly of insect nicotinic acetylcholine receptor heteromers (PMID:32611810).

1. 2004 High

   Established TMX3 as a new ER membrane-anchored PDI-family oxidoreductase, answering what kind of enzyme it is and where it acts.

   Evidence Immunofluorescence, membrane fractionation, CD spectroscopy, in vitro oxidase and redox-potential assays on the recombinant luminal domain

   PMID:15623505

   Open questions at the time

   • In vivo physiological substrates not identified
   • Mechanism of catalytic-cysteine reoxidation unaddressed
2. 2007 High

   Resolved the luminal domain organization, showing how a redox-inactive thioredoxin-like domain stabilizes the adjacent redox-active domain.

   Evidence Recombinant a/ab/abb' constructs analyzed by NMR/biophysics, chemical denaturation, limited proteolysis, and modeling

   PMID:17881353

   Open questions at the time

   • Role of the b' domain not defined
   • Structural consequences for substrate binding not shown
3. 2010 Medium

   Determined that TMX3 is not re-oxidized by Ero1α, distinguishing its redox cycling from canonical PDI enzymes.

   Evidence Mixed-disulfide trapping and co-IP in normal and ERO1-deficient cells (negative result for TMX3)

   PMID:20802462

   Open questions at the time

   • The actual oxidant/reductant partner of TMX3 remains unidentified
   • Negative result does not exclude indirect/low-affinity coupling
4. 2010 High

   Linked TMX3 redox-active function to a developmental phenotype, showing its catalytic domain is required for eye morphogenesis.

   Evidence Zebrafish morpholino knockdown with wild-type vs. patient missense human mRNA rescue and islet-1 retinal labeling

   PMID:20485507

   Open questions at the time

   • Substrates relevant to eye development unknown
   • Causal role of the human variant in disease not established by family genetics here
5. 2009 Medium

   Defined TMX3 surface behavior in platelets, distinguishing it from activation-mobilized thiol isomerases.

   Evidence Flow cytometry, cell-surface biotinylation, immunoblot, and gene array in platelets/megakaryocytes

   PMID:19995400

   Open questions at the time

   • Functional role of surface TMX3 on platelets undefined
   • Mechanism of surface presentation despite ER-retrieval signal unexplained
6. 2015 Medium

   Implicated TMX3 oxidoreductase activity in protein-thiol homeostasis relevant to mutant huntingtin clearance.

   Evidence In vitro oxidoreductase screen plus lentiviral striatal overexpression in a mouse HD model with mHTT and atrophy readouts

   PMID:26664998

   Open questions at the time

   • Direct TMX3-mHTT interaction not shown
   • Mechanism of soluble mHTT reduction unresolved
7. 2019 Medium

   Connected TMX3 to inter-organelle signaling, showing it promotes ER-mitochondria communication and restrains ROS to support NFAT1-dependent melanoma growth.

   Evidence siRNA knockdown with mitochondrial morphology/bioenergetics, ROS measurement, NFAT1 reporters, and xenografts

   PMID:31304984

   Open questions at the time

   • Molecular substrate at ER-mitochondria contacts unidentified
   • Single-lab finding without orthogonal genetic confirmation
8. 2020 High

   Revealed a novel chaperone-like role, with TMX3 acting as an essential cofactor for functional assembly of insect nAChR heteromers.

   Evidence Heterologous expression in Xenopus oocytes with two-electrode voltage-clamp across multiple insect receptor subtypes

   PMID:32611810

   Open questions at the time

   • Whether redox activity is required for this assembly role not dissected
   • Relevance to mammalian receptor folding unknown
9. 2024 Low

   Identified a candidate substrate-modulating interaction, TMX3 binding MT5-MMP and enhancing its η-secretase activity.

   Evidence Yeast two-hybrid screen of brain cDNA plus sAPPη production readout

   PMID:38345408

   Open questions at the time

   • No co-IP/pulldown confirmation of direct binding
   • Physiological relevance to APP processing untested
10. 2025 Low

    Reported extracellular/secreted TMX3 in endothelial cells, extending its detected localization beyond the ER.

    Evidence Impermeable thiol labeling and mass spectrometry-based redox proteomics after diamide treatment

    PMID:40712755

    Open questions at the time

    • Single proteomics method without functional follow-up
    • Mechanism of secretion despite ER-retrieval signal unexplained

• The physiological substrates of TMX3 and the in vivo redox partner that reoxidizes its CGHC active site remain unidentified across all reported contexts.
• No defined endogenous protein substrate
• Reoxidation pathway unknown (not Ero1α)
• Link between redox chemistry and the eye, melanoma, and nAChR phenotypes not mechanistically unified